- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Validation of increased sample stability using the AccuCyte®-CyteFinder® CTC Platform to improve logistics in global clinical trials

# Validation of increased sample stability using the AccuCyte®-CyteFinder® CTC Platform to improve logistics in global clinical trials

Shipping blood to a central processing lab inside a narrow window is what limits where a global circulating tumor cell trial can enrol; this AACR 2022 poster reports validation of a 5-day hold in the AccuCyte collection tube, a higher-capacity prep kit, and frozen slide banking out to the equivalent of 4 years.

Presented by RareCyte and University of Washington.

Read or download to see:

- Blood held 5 days in the AccuCyte collection tube showed no significant loss of CTC recovery or epithelial signal against the same sample processed at 24-72 hours. Ten breast and prostate samples carrying more than 10 CTC per 7.5 mL ran at both timepoints: the mean difference in recovery (24-72 hours minus 120 hours) was -17.3%, i.e. the 5-day draws recovered more on average, with the 95% CI of the mean (-47.5, 12.8) crossing zero and the 95% limits of agreement (-100.0, 65.3) staying wide at this sample size. Two of the ten pairs did move on CK/EpCAM signal, and both were higher at 120 hours rather than lower.

- The higher-capacity AccuCyte prep kit gave CTC recovery equivalent to the version it replaces. New-kit-to-old-kit recovery ratios were read across 30 spiked tube pairs and 14 breast and prostate clinical pairs selected for 10+ CTC in at least one partner, with the median taken over all pairs. The flagged outliers show what that ratio is made of: 0.5 and 23.9 on the spikes, and a clinical 3.3 that is simply 10 CTC against 3.

- Slides banked at -20°C held through the equivalent of 4 years of storage, with estrogen receptor the exception. An accelerated-aging arm at 4°C modelled 4 years for the HER2/ER assay on BT474 cells and 5 years for the AR/SYP assay on 22Rv1 cells. Cell recovery, CK/EpCAM, CD45, HER2, SYP and AR each stayed above the lower limit of performance acceptability drawn on their panels; ER did not, which is why the poster's own results statement reaches only to most biomarkers tested.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/e35dfc002f133eaedcf9005374c5ce828f4dc193.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/e35dfc002f133eaedcf9005374c5ce828f4dc193.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025
### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/bf293dca89c166ae45c117d42bec62d06749f553.pdf) CyteFinder 2024
### Real-time monitoring of CTC number, biomarker expression, and kinetics as prognostic and predictive markers in patients with GI malignancies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/bf293dca89c166ae45c117d42bec62d06749f553.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10693413/) CyteFinder Frontiers in Oncology 2023
### Circulating tumor cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10693413/) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) 2026
### Clinical Validation of Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression in Metastatic Prostate Cancer Phenotypes
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) CyteFinder Clinical Cancer Research 2025
### Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299)